When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
William H. Ludlam, MD, PhD, Chief Medical Officer and Vice President of Clinical Development at Recordati Rare Diseases, Inc., discusses the background, presentation, and diagnosis of Cushing’s disease.…
Erin Dunbar, MD, of @PiedmontHealth, Minesh Mehta, MD, of @MiamiCancerInst, Zosia Piotrawska, MD, MHS, of @MGHMedicine, and Rohan Ramakrishna, MD, of @WeillCornell discuss #brainmetastases in #lungcancer.
